Skip to main content
AVNS
NYSE Industrial Applications And Services

Avanos Medical to be Acquired for $25.00/Share in Definitive Merger Agreement

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
10
Price
$24.7
Mkt Cap
$1.153B
52W Low
$9.303
52W High
$24.75
Market data snapshot near publication time

summarizeSummary

Avanos Medical announced a definitive merger agreement to be acquired for $25.00 per share in cash, while also reporting Q1 2026 results with revenue growth but decreased net income and negative operating cash flow.


check_boxKey Events

  • Definitive Merger Agreement Announced

    Avanos Medical has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash. This transaction, initially disclosed in an 8-K on April 14, 2026, will take the company private and delist its common stock from the NYSE.

  • Q1 2026 Revenue Increased

    Net sales for the three months ended March 31, 2026, rose 8.8% to $182.2 million, up from $167.5 million in the prior-year period, primarily driven by strong demand in Specialty Nutrition Systems.

  • Profitability Declined in Q1

    Operating income decreased by 13.6% to $8.9 million, and net income fell by 22.7% to $5.1 million ($0.11 diluted EPS) compared to $6.6 million ($0.14 diluted EPS) in Q1 2025.

  • Shift to Negative Operating Cash Flow

    The company used $12.3 million in cash from operating activities in Q1 2026, a significant shift from providing $25.7 million in the same period last year, leading to a $24.2 million decrease in cash and cash equivalents during the quarter.


auto_awesomeAnalysis

Avanos Medical has entered into a definitive merger agreement to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash. This transaction, previously announced in an 8-K on April 14, 2026, will result in the company becoming privately held and its stock delisted from the NYSE. The offer price represents a slight premium to the current trading price, providing a clear exit for shareholders. This 10-Q also provides the full Q1 2026 financial results, which show mixed performance with revenue growth but declining profitability and a shift to negative operating cash flow, providing context for the acquisition.

At the time of this filing, AVNS was trading at $24.70 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $9.30 to $24.75. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AVNS - Latest Insights

AVNS
May 05, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
10
AVNS
May 05, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
AVNS
Apr 14, 2026, 4:23 PM EDT
Filing Type: DEFA14A
Importance Score:
7
AVNS
Apr 14, 2026, 1:59 PM EDT
Filing Type: DEFA14A
Importance Score:
7
AVNS
Apr 14, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
10
AVNS
Apr 14, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
AVNS
Mar 12, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
AVNS
Feb 26, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
AVNS
Feb 24, 2026, 4:28 PM EST
Filing Type: 10-K
Importance Score:
8
AVNS
Feb 24, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7